UPDATE: Dawson James Initiates Rockwell Medical at Market Outperform on Execution

Dawson James initiated coverage on Rockwell Medical

with a Market Outperform rating and a $12 price target. Dawson James commented, "We arrive at our target valuation via a combination of methodologies, including DCF and our standardized CAGR valuation approach. Our confidence in RMTI shares achieving our target valuation is derived from the company's demonstrated successful execution of its base business strategy, which targets the nearly 400,000 ESRD patients in the US and approximately 2MM worldwide that require hemodialysis." Rockwell Medical closed at $7.19 on Monday.